CND Life Science, a Phoenix AZ-based medical diagnostics company, raised $5M in Series Seed 2 funding.
The bakers were not disclosed.
The company intends to use the funds to continue commercial scale-up, broaden market education on Syn-One, and advance many R&D activities.
Led by Richard Morello, Chief Executive Officer, and and Todd Levine, MD, Chief Medical Officer and Co-Founder, CND Life Sciences is dedicated to supporting the care of patients facing the potential diagnosis of a neurodegenerative disease and other neurological conditions. Operating a CLIA-certified laboratory in Phoenix, Arizona, CND launched the Syn-One Test as a test to detect, visualize, and quantify misfolded alpha-synuclein located in cutaneous nerve fibers. The test, which analyzes small skin biopsies collected conveniently from the patient in a physician’s office, aids in the diagnosis of a synucleinopathy including Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure.
FinSMEs
03/02/2022